Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/2226/4/09: Merz Pharma v Allergan β€” Botox product monograph comparisons (misleading and unsubstantiated claims; failure to provide substantiation)

Allergan’s Botox monograph made comparative claims vs Dysport (and referenced Xeomin). Panel found several claims misleading/unsubstantiated and ruled…

8 Mar 2026

AUTH/2328/7/10: Trust Clinical Director v Pfizer – conduct of representative (no breach)

A trust clinical director alleged a Pfizer rep was intimidating and applied inappropriate pressure when trying to access…

8 Mar 2026

Cephalon: Lisbon congress hospitality and an internal β€œfeedback” note that read like a party briefing (AUTH/2361/10/10)

Cephalon’s internal congress feedback note described β€œclubbing” and late-night bars with HCPs and urged β€œlets make sure they…

8 Mar 2026

Astellas Pharma: Protopic β€œwhole British summer” leavepiece found inconsistent with SPC sun-exposure warning (AUTH/2418/7/11)

A Protopic leavepiece themed around β€œa whole British summer” was ruled inconsistent with the SPC warning to minimise…

8 Mar 2026

GrΓΌnenthal: complaint about frequency/volume of Palexia promotional mailings (AUTH/2513/6/12) – no breach

Anonymous employee alleged Palexia mailings were triggered after every sales call, risking >8 mailings/year. Panel found mailer was…

8 Mar 2026

AUTH/2541/11/12: GP v Napp β€” Flutiform email sent to NHS address (no breach)

A GP complained about a Flutiform promotional email sent to an NHS address via a third-party agency. The…

8 Mar 2026

BMS/Pfizer v Bayer: Xarelto Eurostroke materialsβ€”β€œprotection from day one” and compliance claims ruled misleading

PMCPA found Bayer’s Xarelto conference panel and booklet claims overstated day-one β€œprotection” and implied proven compliance advantages. Missing…

8 Mar 2026

GSK Seretide: TORCH secondary endpoints used without primary endpoint context in some slide decks and iPad materials (AUTH/2726/8/14)

Anonymous HCP challenged Seretide promotion using TORCH secondary endpoints despite non-significant primary endpoint (p=0.052). PMCPA found some materials…

8 Mar 2026

AUTH/2859/7/16: Health Professional v AstraZeneca (alleged promotion to the public) – No breach

Complaint alleged AstraZeneca’s exhibition stand at a restaurant meeting was visible to the public. Panel found insufficient evidence…

8 Mar 2026

AUTH/2959/5/17: Patient recruitment β€˜finder’s fee’ for market research email (Bayer) – No breach

A health board complained about a market research recruitment email offering a β€˜finder’s fee’ for AF patient interviews.…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training